{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T11:55:31Z","timestamp":1778932531456,"version":"3.51.4"},"reference-count":33,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T00:00:00Z","timestamp":1588982400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The combination of gemcitabine and docetaxel is often used to treat patients with recurrent sarcoma. Nab\u2010paclitaxel is a taxane modified to improve drug exposure and increase intratumoral accumulation and, in combination with gemcitabine, is standard therapy for pancreatic cancer. Applying the dosages and schedule used for pancreatic cancer, we performed a phase II trial to assess the response rate of gemcitabine and nab\u2010paclitaxel in patients with relapsed Ewing sarcoma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Procedure<\/jats:title><jats:p>Using a Simon's two\u2010stage design to identify a response rate of\u00a0\u2265\u00a035%, patients received nab\u2010paclitaxel 125\u00a0mg\/m<jats:sup>2<\/jats:sup> followed by gemcitabine 1000\u00a0mg\/m<jats:sup>2<\/jats:sup> i.v. on days 1, 8, and 15 of four\u2010week cycles. Immunohistochemical analysis of archival tissue was performed to identify possible biomarkers of response.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Eleven patients from four institutions enrolled, with a median age of 22 years (range, 14\u201027). Patients were heavily pretreated (median 3 prior regimens, range, 1\u20107). Thirty\u2010five cycles were administered (median 2, range, 1\u20108). Accrual was stopped after 11 patients, due to only one confirmed partial response. Two other patients had partial responses after two cycles, but withdrew because of adverse effects or progression before confirmation of continued response. The predominant toxicity was myelosuppression, and four (36%) patients were removed due to hematologic toxicity despite pegfilgrastim and dose reductions. Expression of secreted protein, acidic and rich in cysteine (SPARC) and CAV\u20101 in archival tumors was not predictive of clinical benefit in this small cohort of patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In patients with heavily pretreated Ewing sarcoma, the confirmed response rate of 9% was similar to multi\u2010institutional studies of gemcitabine and docetaxel.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.28370","type":"journal-article","created":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T12:26:59Z","timestamp":1589027219000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Phase II trial of gemcitabine and nab\u2010paclitaxel in patients with recurrent Ewing sarcoma: A report from the National Pediatric Cancer Foundation"],"prefix":"10.1002","volume":"67","author":[{"given":"Javier E.","family":"Oesterheld","sequence":"first","affiliation":[{"name":"Department of Pediatric Hematology, Oncology, Bone Marrow Transplantation, and Palliative Care Levine Children's Hospital at Atrium Health Charlotte North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damon R.","family":"Reed","sequence":"additional","affiliation":[{"name":"Department of Interdisciplinary Cancer Management Moffitt Cancer Center Adolescent and Young Adult Program  Tampa Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6054-817X","authenticated-orcid":false,"given":"Bhuvana A.","family":"Setty","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology, Oncology and Bone Marrow Transplantation Nationwide Children's Hospital  Columbus Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4790-9919","authenticated-orcid":false,"given":"Michael S.","family":"Isakoff","sequence":"additional","affiliation":[{"name":"Center for Cancer and Blood Disorders Connecticut Children's Medical Center  Hartford Connecticut"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Thompson","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology\u2010Oncology University of North Carolina Health Care  Chapel Hill North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Pathology Children's Healthcare of Atlanta  Atlanta Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9508-0159","authenticated-orcid":false,"given":"Masanori","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Hematology\u2010Oncology and Bone Marrow Transplant Children's Hospital Colorado  Aurora Colorado"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Loeb","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Department of Developmental and Molecular Biology Albert Einstein College of Medicine  New York City New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiffany","family":"Smith","sequence":"additional","affiliation":[{"name":"National Pediatric Cancer Foundation  Tampa Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rikesh","family":"Makanji","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Imaging and Interventional Radiology Moffitt Cancer Center  Tampa Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brooke L.","family":"Fridley","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Bioinformatics Moffitt Cancer Center  Tampa Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4717-9960","authenticated-orcid":false,"given":"Lars M.","family":"Wagner","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology\u2010Oncology Duke Children's Hospital and Health Center  Durham North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,5,9]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S170585"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30622-8"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-016-1059-2"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24101"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23586"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0176972"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e3181b2598c"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.11007"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2010-0265"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.252"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22813"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1634"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0b013e32830f9046"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25474"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.05.002"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25062"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1304369"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2012.05.001"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1593\/tlo.09109"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2015.05.004"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4936-y"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.187"},{"key":"e_1_2_9_25_1","first-page":"138","article-title":"Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER\u2010ICA) in breast cancer tissue","volume":"8","author":"Remmele W","year":"1987","journal-title":"Pathologe"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25334"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27246"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2007-0215"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0b013e32833aafef"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.15.3483"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.09.140"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn661"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-3222"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S114492"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.28370","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pbc.28370","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.28370","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T04:17:35Z","timestamp":1693282655000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.28370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,9]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["10.1002\/pbc.28370"],"URL":"https:\/\/doi.org\/10.1002\/pbc.28370","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,9]]},"assertion":[{"value":"2020-02-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e28370"}}